Curis, Inc. Appoints James E. Dentzer as Chief Operating Officer and Chief Financial Officer
March 22, 2018 at 07:01 am EDT
Share
Curis, Inc. announced that on March 21, 2018, in connection with the company's entrance into an amended and restated employment agreement with James E. Dentzer, Mr. Dentzer became the chief operating officer and chief financial officer of the company. Mr. Dentzer, age 52, has served as chief financial officer and chief administrative officer since March 2016. He most recently served as chief financial officer of Dicerna Pharmaceuticals, Inc. from December 2013 to December 2015. Prior to that, he was the chief financial officer of Valeritas, Inc. from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the chief financial officer of Amicus Therapeutics, Inc. from October 2006 to October 2009. In prior positions, he spent six years as corporate controller of Biogen and six years in various senior financial roles at E.I. du Pont de Nemours and company in the U.S. and Asia.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
CURIS, INC. 
